Why the SEC is probing Steve Jobs

Behind the investigation into the timing of disclosure of the Apple's 
chief's health problems

By Roger Parloff, senior editor
LAST UPDATED: JANUARY 22, 2009: 5:02 PM ET

NEW YORK (Fortune) -- Apple and its 
CEO-on-leave-but-still-active-sort-of Steve Jobs practically forced 
the Securities and Exchange Commission to look into the adequacy of 
the company?s disclosures about Jobs's medical problems. But the 
investigation may have less to do with Jobs's health than with the 
SEC's.

The SEC, trying to reestablish its credibility after years of 
ignoring explicit and apparently dead-on warnings that Bernard Madoff 
was running a massive Ponzi scheme, could hardly afford to ignore 
Apple's latest in-your-face flip-flop concerning Jobs's battles with 
a rare form of pancreatic cancer, a subject that Jobs and the 
company's board have generally considered Jobs's personal, private 
matter and none of investors' business.

Though the precise scope of the probe, reported yesterday by 
Bloomberg and the Wall Street Journal, is still unclear, it was 
obviously triggered by Jobs's announcement last week that he would be 
taking a six-month medical leave notwithstanding a press statement 
just nine days earlier in which he reassured investors that his gaunt 
appearance was the result of a mere "hormonal imbalance" whose remedy 
would be "simple and straightforward." An Apple spokesman declined to 
comment on the media reports of an SEC inquiry.

Jobs was first diagnosed with the disease in October 2003, but 
disclosed nothing until Aug. 1, 2004, the day after his surgery, when 
he publicly pronounced himself "cured." Then, after Jobs's emaciated 
appearance last June spurred press inquiries over whether the cancer 
had returned, an Apple spokesman claimed Jobs was suffering from "a 
common bug." A month later the New York Times reported that Jobs had 
recently undergone more surgery to address nutritional problems 
apparently stemming from his cancer surgery.

Fears were stoked again - and Apple's (AAPL, Fortune 500) stock price 
began plunging - when Apple announced in December that Jobs would not 
be delivering his traditional keynote address at Macworld. Finally, 
on the morning of Jan. 5, in an effort to stanch the death-bed 
rumors, Apple issued its upbeat, now-infamous claim that, after 
conducting a "sophisticated" battery of blood tests, Jobs's doctors 
now believed he had an easily treatable "hormonal imbalance." Apple 
stock jumped more than 4% that day.

...

http://money.cnn.com/2009/01/22/technology/stevejobs_disclosure.fortune/index.htm

***********************************
* POST TO [email protected] *
***********************************

Medianews mailing list
[email protected]
http://lists.etskywarn.net/mailman/listinfo/medianews

Reply via email to